# Feasibility Trial for a Right Ventricular Failure Platform Trial

> **NCT06570473** · PHASE2 · RECRUITING · sponsor: **University of Alberta** · enrollment: 30 (estimated)

## Conditions studied

- Pulmonary Hypertension
- Right Ventricular Dysfunction
- Right Heart Failure

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Ranolazine

## Key facts

- **NCT ID:** NCT06570473
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06570473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06570473, "Feasibility Trial for a Right Ventricular Failure Platform Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06570473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*